Vaccine epitope mapping is a pivotal step in developing vaccines that are both effective and long-lasting. By identifying specific regions, or epitopes, on pathogens that prompt an immune response, scientists can design vaccines that precisely target these areas. Epitope mapping enables the creation of vaccines that elicit strong, targeted immune reactions, making them more effective in providing immunity. This approach is particularly valuable in addressing infectious diseases with rapidly mutating pathogens, such as influenza or SARS-CoV-2, where focusing on conserved epitopes can offer broader protection. Advanced techniques like bioinformatics, high-throughput screening, and structural biology are expanding the scope of epitope mapping, allowing for more personalized and population-specific vaccine development. This precision in vaccine design helps ensure that vaccines are not only more potent but also safer, minimizing adverse effects associated with broader immune activation.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States